Last reviewed · How we verify
ASLAN Pharmaceuticals — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
0 Phase 3
3 Phase 2
1 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
Therapeutic area mix
- Oncology · 1
- Other · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- ATGC Co., Ltd. · 1 shared drug class
- Addpharma Inc. · 1 shared drug class
- Ahn-Gook Pharmaceuticals Co.,Ltd · 1 shared drug class
- Akeso · 1 shared drug class
- Amgen · 1 shared drug class
- Asahi Kasei Pharma Corporation · 1 shared drug class
- Asan Medical Center · 1 shared drug class
- 3D Medicines (Sichuan) Co., Ltd. · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for ASLAN Pharmaceuticals:
- ASLAN Pharmaceuticals pipeline updates — RSS
- ASLAN Pharmaceuticals pipeline updates — Atom
- ASLAN Pharmaceuticals pipeline updates — JSON
Cite this brief
Drug Landscape (2026). ASLAN Pharmaceuticals — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/aslan-pharmaceuticals. Accessed 2026-06-10.